Alteration of HIV epitope processing and presentation by HIV protease inhibitors

Alteration of HIV epitope processing and presentation by HIV protease inhibitors

Bibliographic Details
Main Authors:	Kourjian G, Boucau J, Shimada M, Lai NY, Le Gall S
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

Mechanisms of HIV Protein Degradation into Epitopes: Implications for Vaccine Design
by: Marijana Rucevic, et al.
Published: (2014-08-01)

Variable processing and presentation of HIV epitopes in dendritic cells and macrophages to CD8 T cells
by: Gourdain P, et al.
Published: (2012-09-01)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.
by: Julie Boucau, et al.
Published: (2020-03-01)

Effect of HIV infection on the expression and the activity of the proteasome in primary CD4 T cells
by: Boucau J, et al.
Published: (2012-09-01)

Sensing HIV Protease and Its Inhibitor Using “Helical Epitope”—Imprinted Polymers
by: Chien-Yu Chou, et al.
Published: (2020-06-01)

Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape.
by: Jens Dinter, et al.
Published: (2015-03-01)

Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M.
by: Werner Smidt
Published: (2013-01-01)

Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes.
by: Kelleher, A, et al.
Published: (2001)

Current and Novel Inhibitors of HIV Protease
by: Jan Konvalinka, et al.
Published: (2009-12-01)

Additivity in the Analysis and Design of HIV Protease Inhibitors
by: Jorissen, Robert N., et al.
Published: (2012)

Computational investigations of HIV-1 protease and protease inhibitors interactions
by: Sham, Hoi Fung
Published: (2014)

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
by: André, P, et al.
Published: (1998)

MAPPING OF PATENTS RELATED TO PROTEASE INHIBITORS AND HIV
by: Romério Rodrigues dos Santos Silva, et al.
Published: (2022-04-01)

Role of Gag in HIV Resistance to Protease Inhibitors
by: Fabrizio Mammano, et al.
Published: (2010-07-01)

Drug-induced modulation of cellular activation during latency reversal changes antigen processing and peptide presentation in primary CD4 T cells
by: J. Boucau, et al.
Published: (2017-12-01)

Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study
by: Kann G, et al.
Published: (2021-08-01)

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
by: Konvalinka Jan, et al.
Published: (2011-08-01)

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir
by: Mahbuba R. Subeha, et al.
Published: (2020-11-01)

Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir
by: Chao Ying, et al.
Published: (2008-02-01)

Safety of protease inhibitors in HIV-infected pregnant women
by: Chougrani I, et al.
Published: (2013-09-01)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
by: Kathleen M S E Reyskens, et al.
Published: (2013-01-01)

Down-regulation of Akt signaling with HIV-1 protease inhibitors
by: Gupta, A, et al.
Published: (2005)

Protease Inhibitor Anti-HIV, Lopinavir, Impairs Placental Endocrine Function
by: Camille Fraichard, et al.
Published: (2021-01-01)

Progress towards the use of HIV protease inhibitors in cancer therapy.
by: Bernhard, E, et al.
Published: (2008)

Progress towards the use of HIV protease inhibitors in cancer therapy
by: Bernhard, E, et al.
Published: (2008)

Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors
by: Sunday N. Okafor, et al.
Published: (2023-08-01)

Oral candidiasis in HIV+ patients under treatment with protease inhibitors
by: Andréa Lusvarghi Witzel, et al.
Published: (2008-12-01)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
by: Nijhuis Monique
Published: (2011-10-01)

Modulation of the LDL receptor and LRP levels by HIV protease inhibitors
by: Huan Tran, et al.
Published: (2003-10-01)

Classification of HIV‑1 Protease Inhibitors by Machine Learning Methods
by: Yang Li, et al.
Published: (2018-11-01)

Inhibitors of Deubiquitinating Enzymes Block HIV-1 Replication and Augment the Presentation of Gag-Derived MHC-I Epitopes
by: Christian Setz, et al.
Published: (2017-08-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir).
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

Gender-specific effects of HIV protease inhibitors on body mass in mice
by: Rosewell Amanda N, et al.
Published: (2007-05-01)

Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children
by: Gomez M Luisa, et al.
Published: (2008-10-01)

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
by: Mohamed Mahdi, et al.
Published: (2020-11-01)

Resistance associated mutations to protease inhibitors on HIV-2 infected patients in Portugal
by: J. Lopes, et al.
Published: (2021-04-01)

The HIV protease inhibitor indinavir reduces immature dendritic cell transendothelial migration.
by: Whelan, K, et al.
Published: (2003)

FMO-guided design of darunavir analogs as HIV-1 protease inhibitors
by: Hathaichanok Chuntakaruk, et al.
Published: (2024-02-01)

Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques
by: Sunday N. Okafor, et al.
Published: (2022-10-01)

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors
by: Gabriele La Monica, et al.
Published: (2021-06-01)